Small Extracellular Vesicle-Derived Circular RNA hsa_circ_0007386 as a Biomarker for the Diagnosis of Pleural Mesothelioma

Cells 2024 June 14 [Link] Sareh Zhand, Jiayan Liao, Alessandro Castorina, Man-Lee Yuen, Majid Ebrahimi Warkiani, Yuen-Yee Cheng Abstract Pleural mesothelioma (PM) is a highly aggressive tumor that is caused by asbestos exposure and lacks effective therapeutic regimens. Current procedures for PM diagnosis are invasive and can take a long time to reach a definitive…

Read More

Comparison of FDG-PET/CT and CT for evaluation of tumor response to nivolumab plus ipilimumab combination therapy and prognosis prediction in patients with unresectable malignant pleural mesothelioma

Oncotarget 2024 June 20 [Link] Kazuhiro Kitajima, Kozo Kuribayashi, Toshiyuki Minami, Hiroyuki Yokoyama, Akifumi Nakamura, Masaki Hashimoto, Takashi Kijima, Seiki Hasegawa, Hayato Kaida, Koichiro Yamakado Abstract Objectives: Results for malignant pleural mesothelioma (MPM) patients following first-line treatment with nivolumab plus ipilimumab obtained with immunotherapy-modified PERCIST (imPERCIST), shown by [18F]fluorodeoxyglucose positron emission tomography/computed tomography (FDG-PET/CT), and…

Read More

Evaluation of the combination of gemcitabine, carboplatin, and lactate dehydrogenase A inhibitor on malignant mesothelioma

Nucleosides, Nucleotides, & Nucleic Acids 2024 June 20 [Link] Marika A Frańczak, Federica Borea, Ryszard T Smoleński, Carlotta Granchi, Filippo Minutolo, Elisa Giovannetti, Godefridus J Peters Abstract Objectives: Lactate dehydrogenase A (LDH-A) catalyzes the last step of glycolysis: supplying cells rapidly but inefficiently with ATP. Many tumors, including malignant mesothelioma (MM), have a high expression…

Read More

Dual Malignancies Discovered: A Rare Case of Malignant Peritoneal Epithelioid Mesothelioma and Lung Adenocarcinoma

Cureus 2024 May 9 [Link] Mark A Potesta Jr, Emma Guld, Jennifer Laman Abstract Clinicians diagnosing malignant peritoneal epithelioid mesothelioma (MPM or MPeM) have historically had challenges due to the low incidence of the disease, as well as the often vague symptomatology that patients present with. Newer advances in technology, specifically in immunocytochemistry, have provided…

Read More

Dendritic cells loaded with allogeneic tumour cell lysate plus best supportive care versus best supportive care alone in patients with pleural mesothelioma as maintenance therapy after chemotherapy (DENIM): a multicentre, open-label, randomised, phase 2/3 study

The Lancet Oncology 2024 June 4 [Link] Joachim G Aerts, Robert Belderbos, Paul Baas, Arnaud Scherpereel, Koen Bezemer, Ilona Enninga, Rob Meijer, Marcella Willemsen, Rossana Berardi, Dean Fennell, Rene Kerstens, Robin Cornelissen, Jan P van Meerbeeck Abstract Background: Dendritic cell immunotherapy has proven to be safe and induces an immune response in humans. We aimed…

Read More

Immediate Versus Deferred Systemic Therapy in Patients With Mesothelioma

Clinical Lung Cancer 2024 April 20 [Link] Sabine Schmid, Luna Zhan, Miguel Garcia, Kristen Dietrich, Khaleeq Khan, Maisha Chowdhury, Michael Herman, Devalben Patel, Fatemeh Zaeimi, Natasha B Leighl, Adrian Sacher, Ronald Feld, Frances A Shepherd, Laura Donahoe, Marc de Perrot, B C John Cho, Geoffrey Liu, Penelope A Bradbury Abstract Background: The 2018 ASCO pleural…

Read More

Dendritic cells loaded with allogeneic tumour cell lysate plus best supportive care versus best supportive care alone in patients with pleural mesothelioma as maintenance therapy after chemotherapy (DENIM): a multicentre, open-label, randomised, phase 2/3 study

The Lancet Oncology 2024 June 4 [Link] Joachim G Aerts, Robert Belderbos, Paul Baas, Arnaud Scherpereel, Koen Bezemer, Ilona Enninga, Rob Meijer, Marcella Willemsen, Rossana Berardi, Dean Fennell, Rene Kerstens, Robin Cornelissen 2, Jan P van Meerbeeck Abstract Background: Dendritic cell immunotherapy has proven to be safe and induces an immune response in humans. We…

Read More

Comparative efficacy of immune checkpoint inhibitors versus chemotherapy alone in diffuse pleural mesothelioma

Thoracic Cancer 2024 June 5 [Link] Xuemei Zhang, Lele Chang, Qian Ma, Qian Zhang, Wansu Xu, Qingwei Li Abstract Background: This study aimed to investigate the effects of immune checkpoint inhibitors (ICIs) versus chemotherapy on the prognosis of real-world diffuse pleural mesothelioma patients in China. Methods: Clinical data of 90 patients with diffuse pleural mesothelioma…

Read More